Monday, April 04, 2016 6:58:14 PM
Depends on perspective... long NKTR 
Actually the launch has been a bit of a disappointment the most impressive thing about it is AZ has inked two pretty good partnership deals. It may still turn out to be a big drug but certainly isn't happening quickly.
I've mentioned it in a couple places but NKTR's most valuable asset a year from now could end up being their first immunotherapy candidate NKTR-214 (they also have a couple other in the pipeline). First patient data should come later this year.
Actually the launch has been a bit of a disappointment the most impressive thing about it is AZ has inked two pretty good partnership deals. It may still turn out to be a big drug but certainly isn't happening quickly.
I've mentioned it in a couple places but NKTR's most valuable asset a year from now could end up being their first immunotherapy candidate NKTR-214 (they also have a couple other in the pipeline). First patient data should come later this year.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
